Clinical trials: Stereotactic Ablative Radiotherapy
Oligometastatic Disease
Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone Lesions
This is a randomised prospective monoinstitutional study comparing radiosurgery at a total dose up to 24 Gy to five fraction stereotactic radiotherapy with simultaneous integrated boost (SIB) up to 50 Gy for the treatment of bone…
- Trial name
- ONES (NCT05679427)
- Testing
- radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively
- Where
- Italy
- Volunteers
- 307 people
- Sponsor
- IRCCS San Raffaele
Non-small Cell Lung Cancers
Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers
The objective of this prospective phase II protocol is to assess the toxicity and efficacy of pentoxifylline and SABR in the re-treatment of recurrent or new lung cancers
- Trial name
- NCT01871454
- Testing
- stereotactic ablative radiotherapy (SABR), Pentoxifylline
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Louisville
Locally Advanced Pancreatic Carcinoma (LAPC)
Surgery Versus Stereotactic Ablative Radiotherapy for Patients With Locally Advanced Pancreatic Cancer With Favourable Biological Response Following Induction Chemotherapy
The primary objective of this study is to assess the added value of surgical exploration with intention for resection compared to MRI guided stereotactic ablative radiotherapy (SABR) in improving overall survival in patients with…
- Trial name
- PREOPANC-4 RCT (NCT07867873)
- Testing
- Pancreatic surgery, MRI guided stereotactic ablative radiotherapy
- Volunteers
- 230 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
This phase II trial compares high-dose rate brachytherapy and stereotactic ablative radiotherapy as monotherapy in treating patients with prostate cancer that has not spread to other parts of the body (localized).
- Conditions
- Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
- Trial name
- NCT04253483
- Testing
- High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer
SBRT Boost for Unfavorable Prostate Cancer'
The purpose of this study is to find out whether giving a short course of focused radiation called an SBRT "boost" is a safe and effective way to treat prostate cancer.
- Trial name
- NCT02016248
- Testing
- Stereotactic body radiotherapy (SBRT) Boost
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- MemorialCare Health System
Renal Tumor
SABR for Renal Tumors
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for…
- Trial name
- NCT03747133
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- University Health Network, Toronto
Breast Cancer Stage IV, Oligometastatic Disease
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy…
- Trial name
- TAORMINA (NCT05377047)
- Testing
- SABR
- Where
- 19 sites in Ireland, Israel and 4 more
- Volunteers
- 345 people
- Sponsor
- Vastra Gotaland Region
Extensive-stage Small-cell Lung Cancer
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
Open-label, single-arm, prospective multicenter phase II clinical trial to determine the efficacy of immunotherapy with durvalumab concomitant with radiochemotherapy, followed by durvalumab maintenance therapy in combination with…
- Trial name
- NCT06223711
- Testing
- Thoracic Radiochemotherapy, durvalumab, Stereotactic radiotherapy of further tumor locations
- Where
- 5 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Universität des Saarlandes
Metastatic Clear Cell Renal Cell Carcinoma
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide…
- Trial name
- NCT01896271
- Testing
- IL-2, Stereotactic Ablative Body Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
NSCLC, NSCLC Stage IV
Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer
This is a prospective, non-randomized, single arm, single institution phase II trial to evaluate the safety and effectiveness of stereotactic ablative radiotherapy (SABR) in oncogene addicted and non-oncogene addicted synchronous…
- Conditions
- NSCLC, NSCLC Stage IV, Oligometastatic Disease, Non Small Cell Lung Cancer
- Trial name
- STARTNEWERA-OM (NCT06207292)
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Radiotherapy Oncology Centre "Santa Maria" Hospital
Breast Cancer, Metastases
SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors
The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer.
- Trial name
- SABR PRIMER (NCT06937281)
- Testing
- SABR
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- British Columbia Cancer Agency
Hepatocellular Cancer, Quality of Life
Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma
Prospective single arm, single center observational study to evaluate Quality of Life (Qol) after stereotactic body radiotherapy for patients with hepatocellular cancer.
- Conditions
- Hepatocellular Cancer, Quality of Life, Stereotactic Body Radiation Therapy, Observational
- Trial name
- LIVERCARE (NCT03253536)
- Testing
- observational
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Biochemical Relapse Free Survival, Complications Rates (Erectile Dysfunction, GI, GU Complications)
HDR Brachytherapy vs SABR in Early-intermediate Prostate Cancer
This is single center prospective phase 2 randomized trial aiming to compare biochemical and clinical relapse free survival and toxicity profiles of stereotactic body radiotherapy (SBRT) versus high dose rate brachytherapy (HDRB)…
- Trial name
- NCT04870567
- Testing
- Stereotactic ablative radiotherapy, High dose rate brachytherapy
- Where
- Russia
- Volunteers
- 350 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Non-small Cell Lung Cancer
Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial
The goal of this clinical trial is to learn if first-line Almonertinib plus upfront stereotactic ablative body radiotherapy (SABR) works to treat EGFR-mutated advanced non-small cell lung cancer.
- Trial name
- NCT06481566
- Testing
- stereotactic ablative body radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Malignant Neoplasms
A Phase I Study Evaluating the Safety of Stereotactic Central Ablative Radiation Therapy (SCART) for Bulky Metastatic or Recurrent Cancer
We aim to evaluate the feasibility and toxicity of testing the tolerance and immunogenic effects of high-dose SCART radiotherapy in patients with bulky metastatic or recurrent cancer in the setting of a single-arm phase I…
- Trial name
- NCT04881981
- Testing
- SCART radiation therapy
- Where
- 4 sites in United States, China
- Volunteers
- 12 people
- Sponsor
- Baptist Health, Louisville
Oligometastatic Renal Cell Carcinoma
SAbR For Oligometastatic Renal Cell Carcinoma
Hypothesis: Stereotactic ablative body radiation (SAbR) prolongs progression-free survival for patients with oligometastatic kidney cancer (RCC) and delays the initiation of systemic therapy.
- Trial name
- NCT02956798
- Testing
- Stereotactic ablative body radiation (SABR)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Texas Southwestern Medical Center
Solid Tumor, Oligometastases
SOFT- Stereotactic Ablative Radiotherapy of Infra-diaphragmatic Soft Tissue Metastases
The SOFT study will evaluate the feasibility and safety of MR-guided stereotactic ablative radiotherapy (SABR) for infra-diaphragmatic soft tissue metastases.
- Conditions
- Solid Tumor, Oligometastases, Soft Tissue Disease
- Trial name
- SOFT (NCT04407897)
- Testing
- Stereotactic radiotherapy
- Where
- Denmark
- Volunteers
- 121 people
- Sponsor
- Herlev Hospital
Early Stage Breast Carcinoma
Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy
Radiation therapy after surgery to remove breast cancer improves control of the breast cancer. Standard therapy after breast conservation surgery is five to six weeks of radiation to the entire breast.
- Trial name
- SIGNAL 2 (NCT02212860)
- Testing
- Stereotactic Body Radiation Then Surgery
- Where
- Canada
- Volunteers
- 139 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lung Cancer Metastatic
Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer
A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to…
- Trial name
- SUPPRESS-NSCLC (NCT04405401)
- Testing
- SABR, Standard of care
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Liver Neoplasms, Hepatocellular Cancer
Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)
This will be multicentre a phase II randomized controlled and open-label trial. It will compare the 6-months objective response (CR+PR) rates obtained with Drug Eluting Bead Trans-Arterial Chemo-Embolization (DEB-TACE) alone…
- Trial name
- HepSTAR (NCT02958163)
- Testing
- Trans-arterial Chemo-Embolization, Doxorubicin, Stereotactic Ablative Radiotherapy
- Where
- 5 sites in Belgium
- Volunteers
- 3 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain